(Circulation. 1999;99:2720-2732.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
Abciximab Facilitates the Rate and Extent of Thrombolysis
Results of the Thrombolysis In Myocardial Infarction (TIMI) 14 Trial
From Brigham and Women's Hospital (E.M.A., R.P.G., C.H.M., E.B.), Boston, Mass; Allegheny General Hospital (C.M.G.), Pittsburgh, Pa; Universitair Ziekenhuis Gasthuisberg (P.C., F.V.d.W.), Leuven, Belgium; Methodist Hospital (N.S.K.), Houston, Tex; Hopital Tenon (A.V.), Paris, France; Royal Victoria Hospital (A.A.J.A., I.M.), Belfast, United Kingdom; Medizinische Klinik II (H.-J.R.), Mainz, Germany; OLVG afdeling Cardiologie (R.V.d.W.), Amsterdam, Netherlands; University of Manitoba Health Sciences Centre (J.D.), Winnipeg, Canada; Eli Lilly, Inc (J.S.), Indianapolis, Ind; and Centocor (K.A.), Malvern, Pa.
Correspondence to Elliott M. Antman, MD, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115. E-mail eantman{at}bustoff.bwh.harvard.edu
Background—The TIMI 14 trial tested the hypothesis that abciximab, the Fab fragment of a monoclonal antibody directed to the platelet glycoprotein (GP) IIb/IIIa receptor, is a potent and safe addition to reduced-dose thrombolytic regimens for ST-segment elevation MI.
Methods and Results—Patients (n=888) with ST-elevation MI presenting <12 hours from onset of symptoms were treated with aspirin and randomized initially to either 100 mg of accelerated-dose alteplase (control) or abciximab (bolus 0.25 mg/kg and 12-hour infusion of 0.125 µg · kg-1 · min-1) alone or in combination with reduced doses of alteplase (20 to 65 mg) or streptokinase (500 000 U to 1.5 MU). Control patients received standard weight-adjusted heparin (70-U/kg bolus; infusion of 15 U · kg-1 · h-1), whereas those treated with a regimen including abciximab received low-dose heparin (60-U/kg bolus; infusion of 7 U · kg-1 · h-1). The rate of TIMI 3 flow at 90 minutes for patients treated with accelerated alteplase alone was 57% compared with 32% for abciximab alone and 34% to 46% for doses of streptokinase between 500 000 U and 1.25 MU with abciximab. Higher rates of TIMI 3 flow at both 60 and 90 minutes were observed with increasing duration of administration of alteplase, progressing from a bolus alone to a bolus followed by either a 30- or 60-minute infusion (P<0.02). The most promising regimen was 50 mg of alteplase (15-mg bolus; infusion of 35 mg over 60 minutes), which produced a 76% rate of TIMI 3 flow at 90 minutes and was tested subsequently in conjunction with either low-dose or very-low-dose (30-U/kg bolus; infusion of 4 U · kg-1 · h-1) heparin. TIMI 3 flow rates were significantly higher in the 50-mg alteplase plus abciximab group versus the alteplase-only group at both 60 minutes (72% versus 43%; P=0.0009) and 90 minutes (77% versus 62%; P=0.02). The rates of major hemorrhage were 6% in patients receiving alteplase alone (n=235), 3% with abciximab alone (n=32), 10% with streptokinase plus abciximab (n=143), 7% with 50 mg of alteplase plus abciximab and low-dose heparin (n=103), and 1% with 50 mg of alteplase plus abciximab with very-low-dose heparin (n=70).
Conclusions—Abciximab facilitates the rate and extent of thrombolysis, producing early, marked increases in TIMI 3 flow when combined with half the usual dose of alteplase. This improvement in reperfusion with alteplase occurred without an increase in the risk of major bleeding. Substantial reductions in heparin dosing may reduce the risk of bleeding even further. Modest improvements in TIMI 3 flow were seen when abciximab was combined with streptokinase, but there was an increased risk of bleeding.
Key Words: thrombolysis • myocardial infarction • platelet aggregation inhibitors • platelets
This article has been cited by other articles:
 |
|
 |
|
  C. Patrono, C. Baigent, J. Hirsh, and G. Roth Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 199S - 233S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 708S - 775S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Ellis, M. Tendera, M. A. de Belder, A. J. van Boven, P. Widimsky, L. Janssens, H.R. Andersen, A. Betriu, S. Savonitto, J. Adamus, et al. Facilitated PCI in Patients with ST-Elevation Myocardial Infarction N. Engl. J. Med., May 22, 2008; 358(21): 2205 - 2217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Giraldez, J. C. Nicolau, R. Corbalan, E. P. Gurfinkel, U. Juarez, J. Lopez-Sendon, A. Parkhomenko, P. Molhoek, S. Mohanavelu, D. A. Morrow, et al. Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis Eur. Heart J., July 1, 2007; 28(13): 1566 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation, May 22, 2007; 115(20): e478 - e534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists Stroke, May 1, 2007; 38(5): 1655 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Maioli, F. Bellandi, M. Leoncini, A. Toso, and R. P. Dabizzi Randomized Early Versus Late Abciximab in Acute Myocardial Infarction Treated With Primary Coronary Intervention (RELAx-AMI Trial) J. Am. Coll. Cardiol., April 10, 2007; 49(14): 1517 - 1524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Saqqur, C. A. Molina, A. Salam, M. Siddiqui, M. Ribo, K. Uchino, S. Calleja, Z. Garami, K. Khan, N. Akhtar, et al. Clinical Deterioration After Intravenous Recombinant Tissue Plasminogen Activator Treatment: A Multicenter Transcranial Doppler Study Stroke, January 1, 2007; 38(1): 69 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. J. Dzau, E. M. Antman, H. R. Black, D. L. Hayes, J. E. Manson, J. Plutzky, J. J. Popma, and W. Stevenson The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions Circulation, December 19, 2006; 114(25): 2871 - 2891. [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Ting, E. H. Yang, and C. S. Rihal Narrative review: reperfusion strategies for ST-segment elevation myocardial infarction. Ann Intern Med, October 17, 2006; 145(8): 610 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Scirica, M. S. Sabatine, D. A. Morrow, C. M. Gibson, S. A. Murphy, S. D. Wiviott, R. P. Giugliano, C. H. McCabe, C. P. Cannon, and E. Braunwald The Role of Clopidogrel in Early and Sustained Arterial Patency After Fibrinolysis for ST-Segment Elevation Myocardial Infarction: The ECG CLARITY-TIMI 28 Study J. Am. Coll. Cardiol., July 4, 2006; 48(1): 37 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Gupta, N. A. Vora, M. B. Horowitz, A. H. Tayal, M. D. Hammer, K. Uchino, E. I. Levy, L. R. Wechsler, and T. G. Jovin Multimodal Reperfusion Therapy for Acute Ischemic Stroke: Factors Predicting Vessel Recanalization Stroke, April 1, 2006; 37(4): 986 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Eikelboom, D. J. Quinlan, S. R. Mehta, A. G. Turpie, I. B. Menown, and S. Yusuf Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction: A Meta-Analysis of the Randomized Trials Circulation, December 20, 2005; 112(25): 3855 - 3867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Part 5: Acute Coronary Syndromes Circulation, November 29, 2005; 112(22_suppl): III-55 - III-72. [Full Text] [PDF]
|
|
|
|
|
|
K.-H. Cho, J. S. Kim, S. U. Kwon, A-H. Cho, and D.-W. Kang Significance of Susceptibility Vessel Sign on T2*-Weighted Gradient Echo Imaging for Identification of Stroke Subtypes Stroke, November 1, 2005; 36(11): 2379 - 2383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Huber, R. D. Caterina, S. D. Kristensen, F. W.A. Verheugt, G. Montalescot, L. B. Maestro, F. V. d. Werf, and for the Task Force on Pre-hospital Reperfusion The Pre-hospital reperfusion therapy: a strategy to improve therapeutic outcome in patients with ST-elevation myocardial infarction Eur. Heart J., October 1, 2005; 26(19): 2063 - 2074. [Full Text] [PDF]
|
|
|
|
 |
|
 A G C Sutton, P G Campbell, R Graham, D J A Price, J C Gray, E D Grech, J A Hall, A A Harcombe, R A Wright, R H Smith, et al. One year results of the Middlesbrough early revascularisation to limit infarction (MERLIN) trial Heart, October 1, 2005; 91(10): 1330 - 1337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Kim, B. H. Lee, D. I. Kim, W. H. Shim, P. Jeon, and T. H. Lee Stent-Assisted Angioplasty of Symptomatic Intracranial Vertebrobasilar Artery Stenosis: Feasibility and Follow-up Results AJNR Am. J. Neuroradiol., June 1, 2005; 26(6): 1381 - 1388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sciagra, G. Parodi, A. Pupi, A. Migliorini, R. Valenti, G. Moschi, G. M. Santoro, G. Memisha, and D. Antoniucci Gated SPECT Evaluation of Outcome After Abciximab-Supported Primary Infarct Artery Stenting for Acute Myocardial Infarction: The Scintigraphic Data of the Abciximab and Carbostent Evaluation (ACE) Randomized Trial J. Nucl. Med., May 1, 2005; 46(5): 722 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Sabatine, D. A. Morrow, R. P. Giugliano, P. B.J. Burton, S. A. Murphy, C. H. McCabe, C. M. Gibson, and E. Braunwald Association of Hemoglobin Levels With Clinical Outcomes in Acute Coronary Syndromes Circulation, April 26, 2005; 111(16): 2042 - 2049. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. De Luca, H. Suryapranata, G. W. Stone, D. Antoniucci, J. E. Tcheng, F.-J. Neumann, F. Van de Werf, E. M. Antman, and E. J. Topol Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction: A Meta-analysis of Randomized Trials JAMA, April 13, 2005; 293(14): 1759 - 1765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Sabatine, C. P. Cannon, C. M. Gibson, J. L. Lopez-Sendon, G. Montalescot, P. Theroux, M. J. Claeys, F. Cools, K. A. Hill, A. M. Skene, et al. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation N. Engl. J. Med., March 24, 2005; 352(12): 1179 - 1189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Lange and L. D. Hillis Concurrent Antiplatelet and Fibrinolytic Therapy N. Engl. J. Med., March 24, 2005; 352(12): 1248 - 1250. [Full Text] [PDF]
|
|
|
|
|
|
K. K. Ray, D. A. Morrow, C. M. Gibson, S. Murphy, E. M. Antman, E. Braunwald, and for the ENTIRE-TIMI 23 Study Group Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy Eur. Heart J., March 1, 2005; 26(5): 440 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Bhatia, G J Clesham, and D R Turner Clinical implications of ST-segment non-resolution after thrombolysis for myocardial infarction J R Soc Med, December 1, 2004; 97(12): 566 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Gibson, S. A. Murphy, A. J. Kirtane, R. P. Giugliano, C. P. Cannon, E. M. Antman, E. Braunwald, and TIMI Study Group Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with st-segment elevation myocardial infarction J. Am. Coll. Cardiol., September 1, 2004; 44(5): 980 - 987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Steiner-Boker, M. Cejna, C. Nasel, E. Minar, and C. W. Kopp Successful Revascularization of Acute Carotid Stent Thrombosis by Facilitated Thrombolysis AJNR Am. J. Neuroradiol., September 1, 2004; 25(8): 1411 - 1413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 234S - 264S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Menon, R. A. Harrington, J. S. Hochman, C. P. Cannon, S. D. Goodman, R. G. Wilcox, H. J. Schunemann, and E. M. Ohman Thrombolysis and Adjunctive Therapy in Acute Myocardial Infarction: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 549S - 575S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. A. Khan Initial Therapy for Acute Myocardial Infarction in the Real World Chest, August 1, 2004; 126(2): 331 - 333. [Full Text] [PDF]
|
|
|
|
|
|
R. Khouzam, D. Apgar, and B. Phibbs Initial Therapy for Acute Myocardial Infarction: Socioeconomic Implications and Limitations Chest, August 1, 2004; 126(2): 457 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J V Patel and H Bardgett Acute limb ischaemia Imaging, August 1, 2004; 16(3): 253 - 263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Goto, N. Tamura, and H. Ishida Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions J. Am. Coll. Cardiol., July 21, 2004; 44(2): 316 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. I. Simon and M. Sakuma Platelet disaggregation: Putting time on your side in acute myocardial infarction J. Am. Coll. Cardiol., July 21, 2004; 44(2): 324 - 326. [Full Text] [PDF]
|
|
|
|
|
|
G. Montalescot, M. Borentain, L. Payot, J. P. Collet, and D. Thomas Early vs Late Administration of Glycoprotein IIb/IIIa Inhibitors in Primary Percutaneous Coronary Intervention of Acute ST-Segment Elevation Myocardial Infarction: A Meta-analysis JAMA, July 21, 2004; 292(3): 362 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Waters II, K. P. Singh, M. T. Roe, M. Lotfi, M. H. Sketch Jr, K. W. Mahaffey, L. K. Newby, J. H. Alexander, R. A. Harrington, R. M. Califf, et al. Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction J. Am. Coll. Cardiol., June 16, 2004; 43(12): 2153 - 2159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Montalescot, H R Andersen, D Antoniucci, A Betriu, M J de Boer, L Grip, F J Neumann, and M T Rothman Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction Heart, June 1, 2004; 90(6): e37 - e37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Antman and F. Van de Werf Pharmacoinvasive Therapy: The Future of Treatment for ST-Elevation Myocardial Infarction Circulation, June 1, 2004; 109(21): 2480 - 2486. [Full Text] [PDF]
|
|
|
|
|
|
M. Shimpo, D. A. Morrow, E. O. Weinberg, M. S. Sabatine, S. A. Murphy, E. M. Antman, and R. T. Lee Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction Circulation, May 11, 2004; 109(18): 2186 - 2190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M A Brouwer, N Clappers, and F W A Verheugt Adjunctive treatment in patients treated with thrombolytic therapy Heart, May 1, 2004; 90(5): 581 - 588. [Full Text] [PDF]
|
|
|
|
|
|
G. De Luca, N. Ernst, F. Zijlstra, A. W. J. van't Hof, J. C. A. Hoorntje, J.-H. E. Dambrink, A. T. M. Gosslink, M.-J. de Boer, and H. Suryapranata Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty J. Am. Coll. Cardiol., April 21, 2004; 43(8): 1363 - 1367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Gibson, J. Karha, S. A. Murphy, J. A. de Lemos, D. A. Morrow, R. P. Giugliano, M. T. Roe, R. A. Harrington, C. P. Cannon, E. M. Antman, et al. Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction J. Am. Coll. Cardiol., April 7, 2004; 43(7): 1170 - 1176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Straub, U. Junghans, V. Jovanovic, H. J. Wittsack, R. J. Seitz, and M. Siebler Systemic Thrombolysis With Recombinant Tissue Plasminogen Activator and Tirofiban in Acute Middle Cerebral Artery Occlusion Stroke, March 1, 2004; 35(3): 705 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M W H Behan and R F Storey Antiplatelet therapy in cardiovascular disease Postgrad. Med. J., March 1, 2004; 80(941): 155 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Lincoff Coupling Drug and Catheter Therapy for Myocardial Infarction JAMA, February 25, 2004; 291(8): 1000 - 1002. [Full Text] [PDF]
|
|
|
|
|
|
H. S. Gurm, A. M. Lincoff, D. Lee, W. H. W. Tang, G. Jia, J. E. Booth, R. M. Califf, E. M. Ohman, F. Van de Werf, P. W. Armstrong, et al. Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: Lessons from the GUSTO V trial J. Am. Coll. Cardiol., February 18, 2004; 43(4): 542 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Roe, C. L. Green, R. P. Giugliano, C. M. Gibson, K. Baran, M. Greenberg, S. T. Palmeri, S. Crater, K. Trollinger, K. Hannan, et al. Improved speed and stability of st-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute st-segment elevation myocardial infarction J. Am. Coll. Cardiol., February 18, 2004; 43(4): 549 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Qureshi, A. M. Siddiqui, S. H. Kim, R. A. Hanel, A. R. Xavier, J. F. Kirmani, M. F. K. Suri, A. S. Boulos, and L. N. Hopkins Reocclusion of Recanalized Arteries during Intra-arterial Thrombolysis for Acute Ischemic Stroke AJNR Am. J. Neuroradiol., February 1, 2004; 25(2): 322 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Gibson, D. S. Pinto, S. A. Murphy, D. A. Morrow, H.-P. Hobbach, S. D. Wiviott, R. P. Giugliano, C. P. Cannon, E. M. Antman, E. Braunwald, et al. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1535 - 1543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. W. Kopp, S. Steiner, C. Nasel, D. Seidinger, I. Mlekusch, W. Lang, A. Bartok, R. Ahmadi, and E. Minar Abciximab Reduces Monocyte Tissue Factor in Carotid Angioplasty and Stenting Stroke, November 1, 2003; 34(11): 2560 - 2567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. W.A. Verheugt Combining glycoprotein blockers with fibrinolysis: a bold stroke? Eur. Heart J., October 2, 2003; 24(20): 1801 - 1803. [Full Text] [PDF]
|
|
|
|
|
|
S. Savonitto, P.W. Armstrong, A.M. Lincoff, G. Jia, C.A. Sila, J. Booth, P. Terrosu, C. Cavallini, H.D. White, D. Ardissino, et al. Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction: Dichotomous response as a function of age in the GUSTO V trial Eur. Heart J., October 2, 2003; 24(20): 1807 - 1814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Dauerman and B. E. Sobel Synergistic treatment of ST-segmentelevation myocardial infarction with pharmacoinvasive recanalization J. Am. Coll. Cardiol., August 20, 2003; 42(4): 646 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Seitz, M. Hamzavi, U. Junghans, P. A. Ringleb, C. Schranz, and M. Siebler Thrombolysis With Recombinant Tissue Plasminogen Activator and Tirofiban in Stroke: Preliminary Observations Stroke, August 1, 2003; 34(8): 1932 - 1935. [Abstract] [Full Text] |